Comparative Pharmacology
Head-to-head clinical analysis: CEFTIN versus CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFTIN versus CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER.
CEFTIN vs CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ceftin (cefuroxime axetil) is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically transpeptidases, thereby disrupting peptidoglycan cross-linking. This leads to cell lysis and death primarily during active cell division.
Cefuroxime is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
250-500 mg orally twice daily for 10 days; for community-acquired pneumonia, 500 mg twice daily for 10 days. Intravenous: 750-1500 mg every 8 hours.
750 mg to 1.5 g intravenously every 8 hours; for severe infections, up to 1.5 g every 6 hours.
None Documented
None Documented
Terminal elimination half-life: 1-2 hours (normal renal function); prolonged to 15-20 hours in severe renal impairment (CrCl <10 mL/min).
Terminal elimination half-life: 1.2-1.6 hours (prolonged to 15-22 hours in severe renal impairment, CrCl <10 mL/min); requires dose adjustment in renal failure
Renal: 80-90% unchanged via glomerular filtration and tubular secretion; biliary/fecal: <5%.
Renal: 80-90% unchanged via glomerular filtration and tubular secretion; fecal: <1%
Category C
Category A/B
Cephalosporin Antibiotic
Cephalosporin Antibiotic